<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02288819</url>
  </required_header>
  <id_info>
    <org_study_id>ZOL-DIPSTICK</org_study_id>
    <nct_id>NCT02288819</nct_id>
  </id_info>
  <brief_title>Spot Urinary Analysis to Assess Loop Diuretic Efficiency in Stable Heart Failure</brief_title>
  <acronym>DIPSTICK</acronym>
  <official_title>Diuretic Efficiency in Patients With Stable Heart Failure: Ion Excretion Capacity of the Kidneys (DIPSTICK) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasselt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ziekenhuis Oost-Limburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hasselt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess whether the urinary sodium/creatinine or
      chloride/creatinine ratio might predict successful downtitration of loop diuretics in
      patients with stable heart failure without clinical signs of volume overload. In addition,
      this study will provide information on loop diuretic efficiency and urinary electrolyte
      composition after intake of diuretics in stable outpatients with heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment and a lack of funding to complete further follow-up
  </why_stopped>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Successful Downtitration of Loop Diuretics (no Weight Increase &gt;1,5 kg)</measure>
    <time_frame>7 days after baseline</time_frame>
    <description>After baseline evaluation, loop diuretics are temporarily downtitrated or stopped for 7 consecutive days. The patient is instructed to measure his/her weight in the morning of these days, immediately after waking up, on the same balance. In case of weight increase &gt;1,5 kg, the original dose of diuretics is restored. To check this, patients are contacted by phone after 3 and 7 days. If the patient has not gained &gt;1,5 kg of weight after 7 days, loop diuretics are considered to be successfully downtitrated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>30 days after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Rehospitalized for Heart Failure</measure>
    <time_frame>30 days after baseline</time_frame>
    <description>Unplanned hospital admission for symptoms of congestion and/or low output heart failure requiring either intravenous therapy and/or increase of oral diuretics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Requiring a Dose Increase in Loop Diuretics</measure>
    <time_frame>30 days after baseline</time_frame>
    <description>Dose increase of oral maintenance therapy with loop diuretics compared to the final dose achieved in the study 7 days after baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight Change</measure>
    <time_frame>7 days after baseline</time_frame>
    <description>Weight change [kg] 7 days after baseline compared to baseline weight.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Weight Change</measure>
    <time_frame>30 days after baseline</time_frame>
    <description>Weight change [kg] 30 days after baseline compared to weight 7 days after baseline (after achieving the final dose of loop diuretics).</description>
  </other_outcome>
  <other_outcome>
    <measure>Self-reported Orthopnea</measure>
    <time_frame>30 days after baseline</time_frame>
    <description>The patient is contacted by phone 30 days after baseline and asked for self-reported orthopnea.</description>
  </other_outcome>
  <other_outcome>
    <measure>Self-reported Lower Leg Edema</measure>
    <time_frame>30 days after baseline</time_frame>
    <description>The patient is contacted by phone 30 days after baseline and asked for self-reported presence of lower leg edema.</description>
  </other_outcome>
  <other_outcome>
    <measure>New York Heart Association (NYHA) Functional Class</measure>
    <time_frame>30 days after baseline</time_frame>
    <description>NYHA class is a semi-quantitative measurement of functional capacity on a scale from 1 to 4:
No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).
Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).
Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.
Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.
For the purpose of this outcome parameter, the patient is contacted by phone 30 days after baseline and NYHA functional class is assessed by a study investigator.</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>6 months after baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rehospitalization for Heart Failure</measure>
    <time_frame>6 months after baseline</time_frame>
    <description>Unplanned hospital admission for symptoms of congestion and/or low output heart failure requiring either intravenous therapy and/or increase of oral diuretics.</description>
  </other_outcome>
  <other_outcome>
    <measure>Dose Increase of Loop Diuretics</measure>
    <time_frame>6 months after baseline</time_frame>
    <description>Dose increase of oral maintenance therapy with loop diuretics compared to the final dose achieved in the study 7 days after baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight Change</measure>
    <time_frame>7 days after baseline</time_frame>
    <description>Weight change [kg] 7 days after baseline compared to baseline weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>30 days after baseline</time_frame>
    <description>The patient is contacted by phone 30 days after baseline and NYHA functional class is assessed by a study investigator.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Loop diuretic downtitration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Scheduled downtitration of maintenance loop diuretic dose while monitoring weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Weight monitoring</intervention_name>
    <description>The body weight of patients is measured each morning in identical conditions on the same balance during 7 days</description>
    <arm_group_label>Loop diuretic downtitration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loop diuretic downtitration</intervention_name>
    <description>The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.
In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.
In case of a total daily maintenance dose &gt;40 mg furosemide OR &gt;1 mg bumetanide OR &gt;20 mg torsemide, the loop diuretic dose is halved.</description>
    <arm_group_label>Loop diuretic downtitration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has a left ventricular ejection fraction &lt;40% or has been previously
             hospitalized with a primary diagnosis of heart failure

          -  Patient receives a daily maintenance dose of loop diuretics

        Exclusion Criteria:

          -  Patient was hospitalized for heart failure &lt;3 months before study inclusion

          -  The maintenance dose of loop diuretics was changed &lt;3 months before study inclusion

          -  The maintenance dose of renin-angiotensin-aldosterone system blockers or beta-blocker
             medication was changed &lt;3 months before study inclusion

          -  Cardiac resynchronization therapy (CRT) was initiated &lt;3 months before study inclusion

          -  At the moment of inclusion, the patient has either one of the following signs of
             volume overload: lower leg edema +2/4, ascites, lung congestion

          -  Patient is not able to measure his/her weight safely and correct at home
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilfried Mullens, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ziekenhuis Oost-Limburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederik H Verbrugge, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ziekenhuis Oost-Limburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <state>Limburg</state>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <results_reference>
    <citation>Martens P, Verbrugge FH, Boonen L, Nijst P, Dupont M, Mullens W. Value of routine investigations to predict loop diuretic down-titration success in stable heart failure. Int J Cardiol. 2018 Jan 1;250:171-175. doi: 10.1016/j.ijcard.2017.10.018. Epub 2017 Oct 6.</citation>
    <PMID>29056238</PMID>
  </results_reference>
  <results_reference>
    <citation>Verbrugge FH, Martens P, Boonen L, Nijst P, Verhaert D, Noyens P, De Vusser P, Dupont M, Tang WHW, Mullens W. Loop diuretic down-titration in stable chronic heart failure is often achievable, especially when urinary chloride concentration is low. Acta Cardiol. 2018 Aug;73(4):335-341. doi: 10.1080/00015385.2017.1385152. Epub 2017 Oct 3.</citation>
    <PMID>28971753</PMID>
  </results_reference>
  <results_reference>
    <citation>Boonen L, Verbrugge FH, Nijst P, Noyens P, De Vusser P, Verhaert D, Van Lierde J, Vrolix M, Dupont M, Mullens W. Subclinical volume overload in stable outpatients with chronic heart failure. Acta Cardiol. 2016 Jun;71(3):299-307. doi: 10.2143/AC.71.3.3152090.</citation>
    <PMID>27594125</PMID>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>November 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2014</study_first_posted>
  <results_first_submitted>October 24, 2017</results_first_submitted>
  <results_first_submitted_qc>January 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 16, 2019</results_first_posted>
  <last_update_submitted>January 15, 2019</last_update_submitted>
  <last_update_submitted_qc>January 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ziekenhuis Oost-Limburg</investigator_affiliation>
    <investigator_full_name>Wilfried Mullens, MD PhD</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>loop diuretics</keyword>
  <keyword>heart failure</keyword>
  <keyword>natriuresis</keyword>
  <keyword>urinary analysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Outpatient cardiology clinic of a single tertiary centre (Ziekenhuis Oost-Limburg, Genk, Belgium) between December, 2014, and February, 2016.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Loop Diuretic Downtitration</title>
          <description>Scheduled downtitration of maintenance loop diuretic dose while monitoring weight
Weight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
Loop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.
In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.
In case of a total daily maintenance dose &gt;40 mg furosemide OR &gt;1 mg bumetanide OR &gt;20 mg torsemide, the loop diuretic dose is halved.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Loop Diuretic Downtitration</title>
          <description>Scheduled downtitration of maintenance loop diuretic dose while monitoring weight
Weight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
Loop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.
In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.
In case of a total daily maintenance dose &gt;40 mg furosemide OR &gt;1 mg bumetanide OR &gt;20 mg torsemide, the loop diuretic dose is halved.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" lower_limit="61" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Successful Downtitration of Loop Diuretics (no Weight Increase &gt;1,5 kg)</title>
        <description>After baseline evaluation, loop diuretics are temporarily downtitrated or stopped for 7 consecutive days. The patient is instructed to measure his/her weight in the morning of these days, immediately after waking up, on the same balance. In case of weight increase &gt;1,5 kg, the original dose of diuretics is restored. To check this, patients are contacted by phone after 3 and 7 days. If the patient has not gained &gt;1,5 kg of weight after 7 days, loop diuretics are considered to be successfully downtitrated.</description>
        <time_frame>7 days after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Loop Diuretic Downtitration</title>
            <description>Scheduled downtitration of maintenance loop diuretic dose while monitoring weight
Weight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
Loop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.
In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.
In case of a total daily maintenance dose &gt;40 mg furosemide OR &gt;1 mg bumetanide OR &gt;20 mg torsemide, the loop diuretic dose is halved.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Successful Downtitration of Loop Diuretics (no Weight Increase &gt;1,5 kg)</title>
          <description>After baseline evaluation, loop diuretics are temporarily downtitrated or stopped for 7 consecutive days. The patient is instructed to measure his/her weight in the morning of these days, immediately after waking up, on the same balance. In case of weight increase &gt;1,5 kg, the original dose of diuretics is restored. To check this, patients are contacted by phone after 3 and 7 days. If the patient has not gained &gt;1,5 kg of weight after 7 days, loop diuretics are considered to be successfully downtitrated.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Mortality</title>
        <time_frame>30 days after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Loop Diuretic Downtitration</title>
            <description>Scheduled downtitration of maintenance loop diuretic dose while monitoring weight
Weight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
Loop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.
In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.
In case of a total daily maintenance dose &gt;40 mg furosemide OR &gt;1 mg bumetanide OR &gt;20 mg torsemide, the loop diuretic dose is halved.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Rehospitalized for Heart Failure</title>
        <description>Unplanned hospital admission for symptoms of congestion and/or low output heart failure requiring either intravenous therapy and/or increase of oral diuretics.</description>
        <time_frame>30 days after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Loop Diuretic Downtitration</title>
            <description>Scheduled downtitration of maintenance loop diuretic dose while monitoring weight
Weight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
Loop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.
In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.
In case of a total daily maintenance dose &gt;40 mg furosemide OR &gt;1 mg bumetanide OR &gt;20 mg torsemide, the loop diuretic dose is halved.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Rehospitalized for Heart Failure</title>
          <description>Unplanned hospital admission for symptoms of congestion and/or low output heart failure requiring either intravenous therapy and/or increase of oral diuretics.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Requiring a Dose Increase in Loop Diuretics</title>
        <description>Dose increase of oral maintenance therapy with loop diuretics compared to the final dose achieved in the study 7 days after baseline.</description>
        <time_frame>30 days after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Loop Diuretic Downtitration</title>
            <description>Scheduled downtitration of maintenance loop diuretic dose while monitoring weight
Weight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
Loop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.
In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.
In case of a total daily maintenance dose &gt;40 mg furosemide OR &gt;1 mg bumetanide OR &gt;20 mg torsemide, the loop diuretic dose is halved.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Requiring a Dose Increase in Loop Diuretics</title>
          <description>Dose increase of oral maintenance therapy with loop diuretics compared to the final dose achieved in the study 7 days after baseline.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Change</title>
        <description>Weight change [kg] 7 days after baseline compared to baseline weight.</description>
        <time_frame>7 days after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Loop Diuretic Downtitration</title>
            <description>Scheduled downtitration of maintenance loop diuretic dose while monitoring weight
Weight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
Loop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.
In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.
In case of a total daily maintenance dose &gt;40 mg furosemide OR &gt;1 mg bumetanide OR &gt;20 mg torsemide, the loop diuretic dose is halved.</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Change</title>
          <description>Weight change [kg] 7 days after baseline compared to baseline weight.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.502" spread="1.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Weight Change</title>
        <description>Weight change [kg] 30 days after baseline compared to weight 7 days after baseline (after achieving the final dose of loop diuretics).</description>
        <time_frame>30 days after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Loop Diuretic Downtitration</title>
            <description>Scheduled downtitration of maintenance loop diuretic dose while monitoring weight
Weight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
Loop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.
In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.
In case of a total daily maintenance dose &gt;40 mg furosemide OR &gt;1 mg bumetanide OR &gt;20 mg torsemide, the loop diuretic dose is halved.</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Change</title>
          <description>Weight change [kg] 30 days after baseline compared to weight 7 days after baseline (after achieving the final dose of loop diuretics).</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.261" spread="1.391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Self-reported Orthopnea</title>
        <description>The patient is contacted by phone 30 days after baseline and asked for self-reported orthopnea.</description>
        <time_frame>30 days after baseline</time_frame>
        <population>1 patient who died before the 30-day follow-up could not be assessed</population>
        <group_list>
          <group group_id="O1">
            <title>Loop Diuretic Downtitration</title>
            <description>Scheduled downtitration of maintenance loop diuretic dose while monitoring weight
Weight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
Loop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.
In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.
In case of a total daily maintenance dose &gt;40 mg furosemide OR &gt;1 mg bumetanide OR &gt;20 mg torsemide, the loop diuretic dose is halved.</description>
          </group>
        </group_list>
        <measure>
          <title>Self-reported Orthopnea</title>
          <description>The patient is contacted by phone 30 days after baseline and asked for self-reported orthopnea.</description>
          <population>1 patient who died before the 30-day follow-up could not be assessed</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Self-reported Lower Leg Edema</title>
        <description>The patient is contacted by phone 30 days after baseline and asked for self-reported presence of lower leg edema.</description>
        <time_frame>30 days after baseline</time_frame>
        <population>1 patient who died before the 30-day follow-up could not be assessed</population>
        <group_list>
          <group group_id="O1">
            <title>Loop Diuretic Downtitration</title>
            <description>Scheduled downtitration of maintenance loop diuretic dose while monitoring weight
Weight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
Loop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.
In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.
In case of a total daily maintenance dose &gt;40 mg furosemide OR &gt;1 mg bumetanide OR &gt;20 mg torsemide, the loop diuretic dose is halved.</description>
          </group>
        </group_list>
        <measure>
          <title>Self-reported Lower Leg Edema</title>
          <description>The patient is contacted by phone 30 days after baseline and asked for self-reported presence of lower leg edema.</description>
          <population>1 patient who died before the 30-day follow-up could not be assessed</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>New York Heart Association (NYHA) Functional Class</title>
        <description>NYHA class is a semi-quantitative measurement of functional capacity on a scale from 1 to 4:
No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).
Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).
Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.
Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.
For the purpose of this outcome parameter, the patient is contacted by phone 30 days after baseline and NYHA functional class is assessed by a study investigator.</description>
        <time_frame>30 days after baseline</time_frame>
        <population>1 patient who died before the 30-day follow-up could not be assessed</population>
        <group_list>
          <group group_id="O1">
            <title>Loop Diuretic Downtitration</title>
            <description>Scheduled downtitration of maintenance loop diuretic dose while monitoring weight
Weight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
Loop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.
In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.
In case of a total daily maintenance dose &gt;40 mg furosemide OR &gt;1 mg bumetanide OR &gt;20 mg torsemide, the loop diuretic dose is halved.</description>
          </group>
        </group_list>
        <measure>
          <title>New York Heart Association (NYHA) Functional Class</title>
          <description>NYHA class is a semi-quantitative measurement of functional capacity on a scale from 1 to 4:
No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).
Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).
Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.
Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.
For the purpose of this outcome parameter, the patient is contacted by phone 30 days after baseline and NYHA functional class is assessed by a study investigator.</description>
          <population>1 patient who died before the 30-day follow-up could not be assessed</population>
          <units>units on a scale from 1 to 4</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>All-cause Mortality</title>
        <time_frame>6 months after baseline</time_frame>
        <population>The study was terminated after every participant reached the 30-day follow-up point because of slow recruitment and a lack of funding to complete further follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Loop Diuretic Downtitration</title>
            <description>Scheduled downtitration of maintenance loop diuretic dose while monitoring weight
Weight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
Loop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.
In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.
In case of a total daily maintenance dose &gt;40 mg furosemide OR &gt;1 mg bumetanide OR &gt;20 mg torsemide, the loop diuretic dose is halved.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality</title>
          <population>The study was terminated after every participant reached the 30-day follow-up point because of slow recruitment and a lack of funding to complete further follow-up</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Rehospitalization for Heart Failure</title>
        <description>Unplanned hospital admission for symptoms of congestion and/or low output heart failure requiring either intravenous therapy and/or increase of oral diuretics.</description>
        <time_frame>6 months after baseline</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Dose Increase of Loop Diuretics</title>
        <description>Dose increase of oral maintenance therapy with loop diuretics compared to the final dose achieved in the study 7 days after baseline.</description>
        <time_frame>6 months after baseline</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Weight Change</title>
        <description>Weight change [kg] 7 days after baseline compared to baseline weight.</description>
        <time_frame>7 days after baseline</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Self-reported Orthopnea</title>
        <description>The patient is contacted by phone 30 days after baseline and asked for self-reported orthopnea.</description>
        <time_frame>30 days after baseline</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Self-reported Lower Leg Edema</title>
        <description>The patient is contacted by phone 30 days after baseline and asked for self-reported presence of lower leg edema.</description>
        <time_frame>30 days after baseline</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>NYHA Functional Class</title>
        <description>The patient is contacted by phone 30 days after baseline and NYHA functional class is assessed by a study investigator.</description>
        <time_frame>30 days after baseline</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Loop Diuretic Downtitration</title>
          <description>Scheduled downtitration of maintenance loop diuretic dose while monitoring weight
Weight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
Loop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.
In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.
In case of a total daily maintenance dose &gt;40 mg furosemide OR &gt;1 mg bumetanide OR &gt;20 mg torsemide, the loop diuretic dose is halved.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart failure readmission</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Frederik Verbrugge</name_or_title>
      <organization>Ziekenhuis Oost-Limburg</organization>
      <phone>0473924199 ext +32</phone>
      <email>frederik.verbrugge@zol.be</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

